Crossbow Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $77M
Overview
Engineering multi-specific antibody therapies to precisely activate the immune system against cancer.
Oncology
Technology Platform
A proprietary antibody engineering platform to design and optimize multi-specific antibodies with tailored geometries and immune signaling functions.
Funding History
1Total raised:$77M
Venture$77M
Opportunities
Potential to develop best-in-class immunotherapies for patients who are refractory to current treatments.
Risk Factors
Risk of clinical failure due to on-target/off-tumor toxicity or insufficient efficacy in complex human tumors.
Competitive Landscape
Enters a crowded field of companies developing bispecific antibodies, competing on molecular design and therapeutic index.